Full-Time
Posted on 8/20/2026
Develops combination cancer therapies in oncology
$155k - $170k/yr
Remote in USA + 2 more
More locations: Brisbane, CA, USA | Hayward, CA, USA
Hybrid
Remote work is available within the United States; approximately 10% travel is required.
Bachelor's
See people who can refer or advise you
Arcus Biosciences develops cancer medicines by designing and advancing combination therapies. Its work centers on oncology, with drug candidates tested through clinical trials to evaluate safety and efficacy, and partnerships, licensing deals, and eventual sales to bring therapies to patients. The company’s products are built to work in combination with other treatments to improve cancer outcomes, and tested in trials to determine optimal dosing and synergistic effects. Arcus differentiates itself through a focus on combination strategies and collaboration with partners, research institutions, and healthcare providers, aiming to advance science-led cancer treatments. Its goal is to improve the lives of cancer patients and move toward potential cures by advancing new combination therapies backed by rigorous research and development.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Hayward, California
Founded
2015
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Remote Work Options
Stock Options
Performance Bonus
Arcus Biosciences and Summit Therapeutics enter into clinical trial collaboration to evaluate casdatifan combined with ivonescimab in kidney cancer. July 22, 2026 san francisco biotechnology network news news, syndication comments off on arcus Biosciences and Summit Therapeutics enter into clinical trial collaboration to evaluate casdatifan combined with ivonescimab in kidney cancer. HAYWARD, Calif. & MIAMI-(BUSINESS WIRE) - - $SMMT-Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, and Summit Therapeutics Inc. (Nasdaq: SMMT), a biopharmaceutical company focused on patient-friendly oncology therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical ne Click here to view original post Discover more Geographic Reference Social Networks
Arcus Biosciences announces clinical trial collaboration and supply agreement to evaluate casdatifan in combination with PD-L1/VEGF-A bispecific immunomodulator to treat Kidney Cancer. June 3, 2026 * This collaboration aims to develop a novel treatment regimen that delivers more sustained tumor control in kidney cancer, a cancer of high unmet medical need HAYWARD, Calif.-(BUSINESS WIRE)- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, "BMS"). Under the agreement, Arcus will supply casdatifan, the company's investigational small-molecule HIF-2a inhibitor, to be evaluated as part of the BMS-sponsored Phase 1/2 ROSETTA RCC-208 clinical trial. This trial evaluates pumitamig (BNT327/BMS986545), an investigational PD-L1/VEGF-A bispecific antibody, being jointly developed by BioNTech and Bristol Myers Squibb, alone or in combination with other potential treatment options in advanced renal cell carcinoma (RCC). As part of this clinical trial collaboration, casdatifan combinations will be added as two new arms of ROSETTA RCC-208. Each company will retain development and commercial rights to their respective assets, and the agreement is mutually non-exclusive. "We believe casdatifan can transform the treatment paradigm in kidney cancer, and our development strategy is designed to generate evidence needed to establish casdatifan as a backbone therapy so that every patient has the opportunity to benefit from casdatifan across each line of therapy," said Terry Rosen, Ph.D., chief executive officer of Arcus. "HIF-2a inhibition, PD-L1 and VEGF-A blockade are validated mechanisms in the treatment of kidney cancer with a strong biologic rationale for combination. This strategic collaboration with BMS is a top priority for Arcus in order to potentially deliver an additional effective TKI-free option in the first-line setting." This collaboration is part of Arcus's holistic development strategy that is intended to provide physicians and patients with: 1) a casdatifan-based and only HIF-2a inhibitor-inclusive TKI-sparing first-line treatment; 2) a casdatifan-based TKI-inclusive first-line regimen; 3) a second-line HIF-2a inhibitor treatment that builds on the second-line standard-of-care TKI, cabozantinib; and 4) a late-line therapy that has been clinically validated to also provide benefit in patients previously treated with a HIF-2a inhibitor-based therapy. About Casdatifan (AB521) Casdatifan is a small-molecule inhibitor of hypoxia-inducible factor 2-alpha (HIF-2a), a master switch that turns on hundreds of genes in response to low oxygen levels. In a majority of people with the most common form of kidney cancer (clear cell renal cell carcinoma; ccRCC), genetic anomalies result in the dysregulation of this master switch and transformation of normal kidney cells into cancerous ones. Casdatifan was designed to provide deep and durable inhibition of the HIF-2a pathway. Early clinical studies have shown high response rates and a low primary progression rate relative to clinical benchmarks, warranting further investigation in late-stage studies. Casdatifan, which is administered in pill form once daily, has a safety profile that allows it to be investigated in combination with other treatments. The casdatifan development strategy is designed to generate evidence needed to establish casdatifan as a backbone therapy so that every ccRCC patient has the opportunity to benefit from casdatifan across each line of therapy. In addition to partner-operationalized studies, Arcus is investigating casdatifan across multiple cohorts in the ARC-20 platform study, alone and in combination with other potential new treatment options, including in the: * First-line setting with cohorts evaluating casdatifan plus zimberelimab, an anti-PD-1 (ongoing); and casdatifan plus zimberelimab and ipilimumab, an anti-CTLA-4 (ongoing) * Second-line setting with a cohort evaluating casdatifan plus cabozantinib in immunotherapy (IO)-experienced patients (ongoing) * Late-line setting with a cohort evaluating casdatifan plus a TKI in both HIF-2a inhibitor-experienced and HIF-2a inhibitor-naive patients (planned) Arcus is also enrolling patients for PEAK-1, the global Phase 3 study evaluating casdatifan plus cabozantinib versus cabozantinib in IO-experienced metastatic ccRCC. Arcus expects to complete enrollment in PEAK-1 and to initiate a Phase 3 study in first-line metastatic ccRCC by year-end 2026. Casdatifan is an investigational molecule. Approval from any regulatory authority for its use has not been received, and its safety and efficacy have not been established. Taiho has development and commercial rights in Japan and other countries in Asia, excluding China. Arcus Biosciences holds full rights to casdatifan everywhere else globally. About Pumitamig (BNT327/BMS986545) Pumitamig is a novel investigational bispecific antibody, jointly developed by BioNTech and BMS, combining two complementary, validated mechanisms in oncology into one single molecule. Pumitamig combines PD-L1 checkpoint inhibition aimed at restoring T cells' ability to recognize and destroy tumor cells with the neutralization of VEGF-A. BioNTech and BMS are currently advancing pumitamig in a broad clinical trial program with more than 20 clinical trials currently ongoing or planned to evaluate pumitamig either as a monotherapy or in combination with other treatment modalities targeting different oncogenic pathways in more than 10 solid tumor indications. About Kidney Cancer According to the American Cancer Society, kidney cancer is among the top 10 most commonly diagnosed forms of cancer among both men and women in the U.S., and an estimated 80,450 Americans will be diagnosed with kidney cancer in 2026. ccRCC is the most common type of kidney cancer in adults. If detected in its early stages, the five-year survival rate for kidney cancer is high; for patients with advanced or late-stage metastatic kidney cancer, however, the five-year survival rate is only 19%. For metastatic kidney cancer, targeted drug therapies are one of the main treatment options. About Arcus Biosciences Arcus Biosciences is a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for the treatment of cancer and inflammatory and autoimmune diseases. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of its late-stage portfolio of first- and/or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into registrational clinical trials including casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. For more information about Arcus Biosciences' clinical and preclinical programs, please visit www.arcusbio.com. Arcus Forward-Looking Statements This press release contains forward-looking statements. All statements regarding events or results to occur in the future contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the potential of casdatifan and pumitamig to achieve more sustained tumor control and deliver a TKI-free option in the first-line setting, statements regarding Arcus's development strategies and plans, and the timing and achievement of milestones, including the completion of enrollment in PEAK-1 and the initiation of a Phase 3 study in 1L metastatic ccRCC. All forward-looking statements involve known and unknown risks and uncertainties and other important factors that may cause Arcus's actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, risks associated with: managing Arcus's collaborations; risks associated with manufacturing or supplying casdatifan; the unexpected emergence of adverse events or other undesirable side effects with casdatifan or casdatifan-based combinations; changes in the competitive landscape for Arcus's programs; and the inherent uncertainty associated with pharmaceutical product development and clinical trials. Risks and uncertainties facing Arcus are described more fully in the "Risk Factors" section of Arcus's most recent periodic report filed with the U.S. Securities and Exchange Commission (SEC) and in other filings that Arcus makes with the SEC from time to time, which are available at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Arcus disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release, except to the extent required by law. The Arcus name and logo are trademarks of Arcus Biosciences, Inc. All other trademarks belong to their respective owners. Arcus Investor & Media Inquiries: Holli Kolkey VP of Corporate Affairs (650) 922-1269 [email protected] Maryam Bassiri Director of Corporate Affairs (510) 406-8520 [email protected]
Analysts covering Arcus Biosciences have sharply reduced their revenue forecasts, with consensus estimates for 2026 now at $72 million, down from $91 million previously. This represents a concerning 70% decline from the company's sales over the past 12 months. The 11 analysts maintained their price target of $34.36 despite the downgrade. The revised forecasts suggest an annualised revenue decline of 80% by end-2026, a stark contrast to the company's 3.3% annual growth over the past five years. Arcus Biosciences' outlook appears significantly weaker than the broader industry, where companies are expected to see 22% annual revenue growth. The substantial reduction in estimates may signal concerns for shareholders about the biotechnology company's near-term prospects.
Arcus Biosciences shares rose 5.2% after discontinuing two lung cancer trials following futility analysis, whilst Gilead Sciences will allow its option rights on several early-stage Arcus programmes to lapse in July 2026. The Phase 3 STAR-121 and Phase 2 EDGE-Lung studies for domvanalimab and zimberelimab in metastatic non-small cell lung cancer were halted after pre-planned analysis, though no new safety issues emerged. Zimberelimab plus chemotherapy showed overall survival comparable to pembrolizumab plus chemotherapy. Gilead's decision narrows the collaboration's scope whilst leaving Arcus with full rights to casdatifan outside territories licensed to Taiho. The company's investment narrative now centres on casdatifan and select oncology assets, with revenue projected to decline 10.3% yearly to $178.6 million by 2029.
COO Jennifer Jarrett to exit Arcus Biosciences (RCUS), stay on as advisor. Filing Impact (Moderate) Filing Sentiment Rhea-AI Filing summary. Arcus Biosciences, Inc. reported that Chief Operating Officer Jennifer Jarrett has decided to resign from her role effective March 30, 2026. The company states that her resignation is not due to any disagreement over operations, policies, or practices. Jarrett has entered into a separation agreement under which she will provide periodic advisory services through June 30, 2026, helping support continuity during the transition. In return, Arcus agreed to extend the period during which she may exercise any vested stock options to twelve months after termination, and the agreement includes a standard release of claims. The final separation agreement will be filed with the company's next quarterly Form 10-Q. Insights. COO exit is noteworthy but framed as amicable and structured. The departure of the Chief Operating Officer at Arcus Biosciences is a meaningful management change, but the company emphasizes that it does not stem from any disagreement over business matters. This language is intended to limit concerns about internal conflict or strategic rifts. The separation agreement keeps Jennifer Jarrett involved as an advisor through June 30, 2026, which may help preserve institutional knowledge during leadership transition. Extending her vested option exercise window to twelve months is a relatively employee-friendly term, suggesting a cooperative relationship rather than a contentious exit. The ultimate impact will depend on how Arcus realigns responsibilities and communicates its operational leadership structure in upcoming disclosures. Investors often look to future filings, such as the next Form 10-Q, for additional detail on succession plans and any broader organizational changes tied to a senior executive's resignation. 03/23/2026 - 07:46 AM Faq. Why did Arcus Biosciences (RCUS) announce the resignation of its COO? Arcus Biosciences announced that Chief Operating Officer Jennifer Jarrett will resign effective March 30, 2026. The company explicitly states that her decision is not due to any disagreement regarding its operations, policies, or practices, framing the departure as an amicable leadership transition. When is Arcus Biosciences COO Jennifer Jarrett's resignation effective? Chief Operating Officer Jennifer Jarrett will step down from her role effective March 30, 2026. After that date, she will no longer serve as COO but will remain involved with Arcus Biosciences in an advisory capacity under a separation agreement that runs through June 30, 2026. Will Jennifer Jarrett continue working with Arcus Biosciences (RCUS) after resigning as COO? Yes. Under a separation agreement, Jennifer Jarrett will provide periodic advisory services for Arcus Biosciences through June 30, 2026. This arrangement is designed to support continuity during the leadership transition while she steps away from day-to-day responsibilities as Chief Operating Officer. What compensation terms did Arcus Biosciences agree to in Jennifer Jarrett's separation? In exchange for advisory services, Arcus Biosciences agreed to extend the post-termination stock option exercise period for Jennifer Jarrett to twelve months. This applies to her vested options and effectively gives her more time to exercise equity awards after her COO role ends. Does Arcus Biosciences report any disagreement related to the COO's resignation? No. The company states that Ms. Jarrett's resignation is not the result of any disagreement with Arcus Biosciences regarding its operations, policies, or practices. This wording aims to reassure stakeholders that the leadership change is not driven by internal disputes or governance conflicts. Where can investors find the full details of Jennifer Jarrett's separation agreement with Arcus Biosciences (RCUS)? Arcus Biosciences plans to file the final separation agreement with its next quarterly Form 10-Q. Investors seeking complete legal terms, including any additional provisions beyond the summary, will be able to review the full document once that quarterly report is published. Filing exhibits & attachments. 3 documents